Roivant and Priovant launch rare disease drug Lisraya at $35,000/month
Roivant and Priovant launched newly approved rare disease drug Lisraya at $35,000 a month.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.